Psychological impact of anti-VEGF treatments for wet macular degeneration—a review

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 254, Issue 10, 2016, Pages 1873-1880

  Senra, Hugo ^a   Ali, Zaria ^b   Balaskas, Konstantinos ^b   Aslam, Tariq ^a,b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^c HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

Anti VEGF treatment; Intra vitreal injections; Psychological impact; Wet age related macular degeneration

Indexed keywords

VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANXIETY; ARTICLE; DEPRESSION; HUMAN; INJECTION PAIN; MENTAL HEALTH; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; STRESS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISION; VISUAL ACUITY; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; ANXIETY DISORDER; INTRAVITREAL DRUG ADMINISTRATION; PHYSIOLOGY; PSYCHOLOGY;

ANGIOGENESIS INHIBITORS; ANXIETY DISORDERS; BEVACIZUMAB; DEPRESSIVE DISORDER; HUMANS; INTRAVITREAL INJECTIONS; MENTAL HEALTH; QUALITY OF LIFE; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84989295984     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-016-3384-0     Document Type: Article

References (32)

1. Coleman H, Chan C, Ferris F, Chew E (2008) Age-related macular degeneration. Lancet 372:1835–1845
2. Dawson SR, Mallen CD, Gouldstone MB, Yarham R, Mansell G (2014) The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data. BMC Ophthalmol 14:78
3. Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, McAllister IL, Essex RW, Morlet N, Hunyor AP (2015) Fight retinal blindness study group(∗). Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology 18
4. Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C (2015) Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review. Psychol Health Med 20:296–310
5. McCloud C, Khadka J, Gilhotra JS, Pesudovs K (2014) Divergence in the lived experience of people with macular degeneration. Optom Vis Sci 91:966–974
6. Chua P, Mitrut I, Armbrecht A, Vani A, Aslam T, Dhillon B (2009) Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injection for wet age-related macular degeneration. Arch Ophthalmol 127:939–940
7. Henriksen K, Adhami S (2010) Patient experience of intravitreal injections in AMD. Int J Ophthalmic Pract 1:68–72
8. Tailor R, Beasley R, Yang Y, Narendran N (2011) Evaluation of patients’ experiences at different stages of the intravitreal injection procedure—What can be improved? Clin Ophthalmol 5:1499
9. Thetford C, Hodge S, Harding S, Taylor S, Knox P (2013) Living with age-related macular degeneration treatment: patient experiences of being treated with ranibizumab (Lucentis)® intravitreal injections. Br J Vis Impair 31:89–101
10. Wang LL, Liu WJ, Liu HY, Xu X (2015) Single-site baseline and short-term outcomes of clinical characteristics and life quality evaluation of Chinese wet age-related macular degeneration patients in routine clinical practice. Chin Med J (Engl) 128:1154–1159
11. Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study—a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540–546
12. Finger RP, Guymer RH, Gillies MC, Keeffe JE (2014) The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology 121:1246–1251
13. Inoue M, Arakawa A, Yamane S, Kadonosono K (2014) Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life. Clin Ophthalmol 8:1711–1716
14. Casten R, Rovner BW, Leiby BE, Tasman W (2010) Depression despite anti-vascular endothelial growth factor treatment of age-related macular degeneration. Arch Ophthalmol 128:506–508
15. Lee WJ, Cho HY, Kim DH, Yu HG, Oh J, Kim JS, Moon SW (2013) Depression of late age-related macular degeneration patients in Korea. Asia Pac J Ophthalmol 2:23–27
16. Sloan FA, Hanrahan BW (2014) The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration. JAMA Ophthalmol 132:456–463
17. Segal O, Segal-Trivitz Y, Nemet AY, Cohen P, Geffen N, Mimouni M (2015) Anxiety levels and perceived pain intensity during intravitreal injections. Acta Ophthalmol. doi:10.1111/aos.12802
18. LaHood B, Sherwood D, Suter A (2011) Comparative assessment of the effectiveness of anaesthesia for intravitreal bevacizumab injection. Clin Exp Ophthalmol 39:184–185
19. Moisseiev E, Regenbogen M, Bartfeld Y, Barak A (2012) Evaluation of pain in intravitreal bevacizumab injections. Curr Eye Res 37:813–817
20. Rifkin L, Schaal S (2012) Factors affecting patients’ pain intensity during in office intravitreal injection procedure. Retina 32:696–700
21. Roth D, Scott I, Gulati N, Prenner J (2006) Patient perceptions of discomfort and changes in vision and functional status associated with intravitreal triamcinolone injection. Am J Ophthalmol 142:492–494
22. Yau G, Jackman C, Hooper P, Sheidow T (2011) Intravitreal injection anesthesia – Comparison of different topical agents: a prospective randomized controlled trial. Am J Ophthalmol 151:333–337.e2, e332
23. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD (2001) Development of the 25-item National Eye Institute visual function questionnaire. Arch Ophthalmol 119:1050–1058
24. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey MB, Leirer VO (1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37–49
25. Bennion AE, Shaw RL, Gibson JM (2012) What do we know about the experience of age related macular degeneration? a systematic review and meta-synthesis of qualitative research. Soc Sci Med 75:976–985
26. Senra H, Barbosa F, Ferreira P, Vieira CR, Perrin PB, Rogers H, Rivera D, Leal I (2015) Psychologic adjustment to irreversible vision loss in adults: a systematic review. Ophthalmology 122:851–861
27. Augustin A, Sahel JA, Bandello F, Dardennes R, Maurel F, Negrini C, Hieke K, Berdeaux G (2007) Anxiety and depression prevalence rates in age-related macular degeneration. Invest Ophthalmol Vis Sci 48:1498–1503
28. Eramudugolla R, Wood J, Anstey KJ (2013) Co-morbidity of depression and anxiety in common age-related eye diseases: a population-based study of 662 adults. Front Aging Neurosci 5:56
29. Casten RJ, Rovner BW (2013) Update on depression and age-related macular degeneration. Curr Opin Ophthalmol 24:239–243
30. Kan C, Silva N, Golden SH, Rajala U, Timonen M, Stahl D, Ismail K (2013) A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care 36:480–489
31. Winkley K, Sallis H, Kariyawasam D, Leelarathna LH, Chalder T, Edmonds ME, Stahl D, Ismail K (2012) Five-year follow-up of a cohort of people with their first diabetic foot ulcer: the persistent role of depression on mortality. Diabetologia 55:303–310
32. Kariyasam DK, Leelarathna L, Winkley K, Stahl D, Ismail K, Edmonds M (2009) Long-term follow-up of a cohort of patients with diabetes and their first foot ulcer-effect of depression on mortality. Diabetologia 52(suppl1):PS 1002–S393, Abstract